Recruiting PHASE2 INTERVENTIONAL 1-arm NCT05450029

Neoadjuvant Chemoradiotherapy Plus Sintilimab for Intermediate/High Immunoscore Locally Advanced Rectal Cancer (SILAR)

Neoadjuvant Chemoradiotherapy Plus Sintilimab for Intermediate/High Immunoscore Locally Advanced Rectal Cancer: A Single-Center, Open-Label, Single-Arm, Phase 2 Trial

Sponsor: GeneCast Biotechnology Co., Ltd.

Conditions Rectal Cancer

Interventions Sintilimab

Updated 6 times since 2022 Last updated: Sep 24, 2023 Started: Jan 1, 2022 Primary completion: Jan 1, 2024 Completion: Jan 1, 2027

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Rectal Cancer, this trial is actively recruiting participants. The trial is conducted by GeneCast Biotechnology Co., Ltd. and has accumulated 6 data snapshots since 2022. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Recruiting PHASE2
Jul 2024 — Sep 2024 [monthly]

Recruiting PHASE2
Oct 2023 — Jul 2024 [monthly]

Recruiting PHASE2
Aug 2023 — Oct 2023 [monthly]

Recruiting PHASE2
May 2023 — Aug 2023 [monthly]

Recruiting PHASE2

▶ Show 1 earlier version

Sep 2022 — May 2023 [monthly]

Recruiting PHASE2

First recorded

Jan 2022

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

GeneCast Biotechnology Co., Ltd.
Yanhong Deng

Data source: Sun Yat-sen University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Guangzhou, China